Over 2 Billion Reasons to Love CRISPR Therapeutics Right Now
Yahoo Finance ·
Like most other up-and-coming biopharma companies, CRISPR Therapeutics ( CRSP 1.53% ) brings both risk and reward to the table. This particular name, however, may bring less risk than it seems at first blush, and perhaps even more reward. CRISPR Therapeutics is a developer of gene therapies for disease, by the way. Specifically, the company's founders figured out how to cut a damaged segment out of a DNA strand and replace it with a corrected one. It even has an approved therapy on the market, with more in the works. As you might imagine, though, such development isn't cheap. Like other newcomers to the biopharma business , CRISPR Therapeutics is consuming cash at a pretty brisk clip. However, it's different from most others of this ilk. Unlike its similarly sized and similarly aged peers, this $5.9 billion outfit is sitting on $2.4 billion worth of cash and marketable securities that can be readily converted into cash if and when the need arises. At its current rate of cash burn, that's a little over four years' worth of funding without the need for any additional, dilutive fund-raising.
DYAX Investor Sentiment
Bullish (Long) 58% · Bearish (Short) 42%
347 participants
Related News
- Nyxoah reports Q2 2026 preliminary revenue of €7.7M
- Penguin Solutions rockets as Q3 results, guidance top estimates
- Fiserv President Dhivya Suryadevara resigns
- SA analyst: Prepare for volatility as markets stay 'stuck in neutral'
- Business First Bancshares expands advisory services with American Planning acquisition
- Kura Sushi USA Non-GAAP EPS of $0.03 beats by $0.05, revenue of $85.9M misses by $0.56M